Renovaro Biosciences

Renovaro (NASDAQ: RENB) is pioneering AI-driven precision medicine to transform outcomes for cancer and neurology patients – from early detection to personalized treatment. Renovaro’s full-stack Bio-AI platform integrates advanced diagnostics, rapid drug discovery, predictive analytics, and experimental validation to deliver faster, more effective, and individualized care. Through deep learning, multi-omic data, CRISPR models, and phenomics-driven insights, the Renovaro ecosystem – spanning Renovaro Cube, Renovaro Bio, and BioSymetrics – enables a truly end-to-end approach to patient-centered innovation in oncology and neurology. Renovaro is headquartered in Los Angeles, with teams across the United States, Canada, and Europe, and actively collaborates with clinics, hospitals, and research institutions around the world.